[Clinical evaluation of schizophyllan (SPG) in advanced gastric cancer (the second report)--a randomized controlled study].
We reported previously that Schizophyllan (SPG) combined with MMC + 5-FU (MF regimen) or Tegafur (F regimen) had a significant life-prolonging effect over chemotherapeutic regimens in patients with inoperable and recurrent gastric cancer in a randomized controlled study. In the present paper, we have further investigated the effect of SPG on life-span followed-up for more than 2 years. A significant life-prolonging effect of SPG was reconfirmed in patients given either the MF regimen (154 patients) or the F regimen (213 patients). Thus, SPG combined with chemotherapeutics has proved to be useful for treating patients with inoperable and recurrent gastric cancer, resulting in a significant prolongation of life-span without serious side effects despite having no influence on tumor size.
Furue
H
H
Uchino
H
H
Orita
K
K
Kimura
T
T
Goto
Y
Y
Kondo
T
T
Sato
S
S
Takino
T
T
Taguchi
T
T
Nakao
I
I
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004334:Drug Administration Schedule; D005472:Fluorouracil / Q000008:administration & dosage; D006025:Glycosaminoglycans / Q000627:therapeutic use*; D006801:Humans; D016685:Mitomycin; D008937:Mitomycins / Q000008:administration & dosage; D011897:Random Allocation; D012566:Sizofiran / Q000008:administration & dosage / Q000627:therapeutic use*; D013274:Stomach Neoplasms / Q000188:drug therapy*; D005641:Tegafur / Q000008:administration & dosage
D006025:Glycosaminoglycans; D008937:Mitomycins; D005641:Tegafur; D016685:Mitomycin; D012566:Sizofiran; D005472:Fluorouracil